New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
08:09 EDTGNCAGenocea announces Phase 2 GEN-003 optimization trial
Genocea Biosciences announced the start of a Phase 2 dose optimization trial for GEN-003. The Phase 2 dose optimization study will enroll approximately 300 subjects from 17 institutions in the U.S. and will study six combinations of two antigen doses with each of three adjuvant doses alongside a placebo. All subjects will receive three doses of GEN-003 or placebo at 21-day intervals. The primary end point for the study is the change from baseline in viral shedding rate. The study is also designed to evaluate the impact on percentage of days with genital herpes lesions as reported by patients. Subjects receiving GEN-003 will be followed for 12 months after the last dose. Previously the company announced results from its Phase 1/2a clinical trial of GEN-003, which demonstrated, in the 30 microgram dose group, statistically significant reductions from baseline in viral shedding and genital lesion rates of up to 52% and 65% respectively, with a durability of effect to six months after dosing. The company said, "We look forward to announcing interim results from this trial in the middle of 2015.
News For GNCA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2016
08:22 EDTGNCAGenocea commences dosing in Phase 2b study of GEN-003
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use